奈达铂联合紫杉醇同步放化疗治疗中晚期宫颈癌的疗效及不良反应

目的 对比分析奈达铂和顺铂联合紫杉醇同步放化疗治疗中晚期宫颈癌的疗效及毒副作用.方法 选择中晚期宫颈癌患者66例,按照随机数字法分为奈达铂组和顺铂组,各33例.奈达铂组采用紫杉醇35 mg/m2+奈达铂20 mg/m2同步放疗治疗,顺铂组采用紫杉醇35 mg/m2+顺铂20 mg/m2同步放疗治疗.结果 奈达铂组治疗的有效率为97.0％,顺铂组治疗的有效率为90.7％,2组差异无统计学意义(P＞0.05).奈达铂组患者贫血以Ⅰ级为主,顺铂组患者贫血以Ⅰ～Ⅱ为主,2组差异有统计学意义(P＜0.05);中性粒细胞减少、血小板减少、恶心呕吐、腹泻、肝肾功能损伤的发生情况2组无统计学差异(P＞0.05).奈达铂组患者的1、2、3年生存率分别为87.8％,75.7％和57.6％,顺铂组患者的1、2、3年生存率分别为82.7％,63.6％和54.5％,其中奈达铂组1年和2年生存率显著高于顺铂组(P＜0.05).结论 奈达铂和紫杉醇同步放疗治疗中晚期宫颈癌疗效显著,患者依从性好,不良反应尚可耐受.

Efficacy and Adverse Effects of Nedaplatin Combined with Paclitaxel in the Treatment of Advanced Cervical Cancer

Objective To observe the efficacy and toxicity of nedaplatin combined with paclitaxel concurrent radiotherapy and chemotherapy in the treatment of advanced cervical cancer.Methods 66 cases of advanced cervical cancer,according to the random number,were divided into nedaplatin group and cisplatin group,with 33 cases in each group.Nedaplatin group was treated with paclitaxel 35 mg/m2 + nedaplatin 20 mg/m2 synchronous radiotherapy,and cisplatin group was treated with paclitaxel 35 mg/m2 + cisplatin 20 mg/m2 synchrotron radiation therapy.Resuits The effective rate of nedaplatin group was 97.0％,and the effective rate of cisplatin group was 90.7％.There was no significant difference between the 2 groups (P ＞ 0.05);neutropenia,thrombocytopenia,nausea and vomiting,diarrhea,and diarrhea were significantly higher than those of the control group (P ＜0.05).There was no significant difference between the 2 groups (P ＞ 0.05).1,2,and 3-year survival rates were 87.8％,75.7％ and 57.6％ in the nedaplatin group and 82.7％,63.6％ and 54.5％ in the cisplatin group,respectively.1-and 2-year survival rates of nedaplatin group were significantly higher than those of cisplatin group (P ＜ 0.05).Conclusion Neodymidine and paclitaxel in the treatment of advanced cervical cancer is effective,with good compliance,adverse reactions can be tolerated.